Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Blood (2024) 144 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2024-210324

Published: 2024

Journal Articles

Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis

Ethan A. Mack, Meaghan C. Dougher, Ashley M. Ginda, Caitlin Cahill, Melissa Murter, Kevin Schell, Yvette C. Tanhehco, Vijay G. Bhoj, Andrew D. Fesnak, Don L. Siegel, Taku Kambayashi, Nicole A. Aqui, Una O’Doherty

Blood (2024) 143 (11): 1049–1054.

https://doi.org/10.1182/blood.2023021895

Published: 2024

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura

Konstantine Halkidis, Chan Meng, Szumam Liu, Leland Mayne, Don L. Siegel, X. Long Zheng

Blood (2023) 141 (24): 2993–3005.

https://doi.org/10.1182/blood.2022019252

Published: 2023

Includes: Supplemental data

Journal Articles

The Mechanism of Antibody-Mediated Inhibition of ADAMTS13 in Immune Thrombotic Thrombocytopenic Purpura

Chan Meng, Konstantine Halkidis, Szumam Liu, Don L. Siegel, X. Long Zheng

Blood (2022) 140 (Supplement 1): 5527–5528.

https://doi.org/10.1182/blood-2022-166911

Published: 2022

Journal Articles

Ontogeny of the Alloimmune Anti-Canine Factor VIII Inhibitor Response in Severe Hemophilia Α Dogs

Robert Chen, Bhavya S Doshi, Timothy C. Nichols, Michael C. Milone, Ben J. Samelson-Jones, Valder R Arruda, Vijay Bhoj, Don L. Siegel

Blood (2021) 138 (Supplement 1): 3173.

https://doi.org/10.1182/blood-2021-149215

Published: 2021

Journal Articles

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Blood (2021) 138 (Supplement 1): 166.

https://doi.org/10.1182/blood-2021-152664

Published: 2021

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia

Xin He, Zijie Feng, Jian Ma, Sunbin Ling, Yan Cao, Buddha Gurung, Yuan Wu, Bryson W. Katona, Kienan P. O’Dwyer, Don L. Siegel, Carl H. June, Xianxin Hua

Blood (2020) 135 (10): 713–723.

https://doi.org/10.1182/blood.2019002779

Published: 2020

Includes: Supplemental data

Journal Articles

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

Elise A. Chong, Bruce L. Levine, Stephan A. Grupp, Megan M. Davis, Don L. Siegel, Shannon L. Maude, Whitney L. Gladney, Noelle V. Frey, David L. Porter, Wei-Ting Hwang, Emeline R. Chong, Carl H. June, Stephen J. Schuster

Blood (2019) 134 (21): 1873–1875.

https://doi.org/10.1182/blood.2019002258

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Elise A. Chong, MD, James N. Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, David L. Porter, MD, Karen Dengel, BSN, RN, Don L. Siegel, MD PhD, Joan Gilmore, BS, Stefan K. Barta, MD MRCP, MS, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 594.

https://doi.org/10.1182/blood-2019-131078

Published: 2019

Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1863.

https://doi.org/10.1182/blood-2019-131515

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

J. Joseph Melenhorst, PhD, David L. Porter, MD, Lifeng Tian, PhD, Simon F Lacey, PhD BS, Christopher L Nobles, PhD, Joseph A Fraietta, PhD, Noelle V. Frey, MD, Irina Kulikovskaya, Minnal Gupta, Regina M Young, PhD, David E Ambrose, BS, Don L. Siegel, MD PhD, Frederic D Bushman, PhD, Carl H June, MD

Blood (2018) 132 (Supplement 1): 699.

https://doi.org/10.1182/blood-2018-99-117390

Published: 2018

Journal Articles

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

Christopher L Nobles, PhD, John K Everett, Shantan Reddy, Joseph A Fraietta, PhD, David L. Porter, MD, Noelle V. Frey, MD, Stephan A. Grupp, MD PhD, Don L. Siegel, MD PhD, Simon F Lacey, PhD BS, Carl H June, MD, Frederic D Bushman, PhD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2018-99-117034

Published: 2018

Journal Articles

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Elise A. Chong, MD, Bruce L Levine, PhD, Stephan A. Grupp, MD PhD, Megan Davis, PhD, Don L. Siegel, MD PhD, Shannon L. Maude, MD PhD, Whitney Lynn Gladney, PhD, Noelle V. Frey, MD, David L. Porter, MD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 197.

https://doi.org/10.1182/blood-2018-197

Published: 2018

Journal Articles

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Blood (2018) 132 (Supplement 1): 298.

https://doi.org/10.1182/blood-2018-99-115418

Published: 2018

Journal Articles

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Ehren Dancy, MD, Alfred L. Garfall, MD, Adam D. Cohen, MD, Joseph A Fraietta, PhD, Megan Davis, PhD, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Adam Waxman, MD, Aaron P. Rapoport, MD, Michael C. Milone, MD PhD, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2018-99-115319

Published: 2018

NARROW

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura

The Mechanism of Antibody-Mediated Inhibition of ADAMTS13 in Immune Thrombotic Thrombocytopenic Purpura

Ontogeny of the Alloimmune Anti-Canine Factor VIII Inhibitor Response in Severe Hemophilia Α Dogs

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only